Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency Pharmaceutical Investing
RedHill Biopharma Announces Phase IIa 48-Week Final Results for RHB-104 in Multiple Sclerosis Pharmaceutical Investing
Diffusion Pharmaceuticals Files Definitive Proxy Statement for Upcoming Special Meeting of Stockholders Life Science Investing
Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Pharmaceutical Investing
Reata Pharmaceuticals Announces Requested Withdrawal of Registration Statement Due to Adverse Market Conditions Pharmaceutical Investing
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
